-
Vivus' Qsymia appears to cut diabetes risk in some patients
MOUNTAIN VIEW, Calif. — Patients taking a drug used for weight loss were able to reduce their chances of developing Type 2 diabetes, according to a new study.
According to data from a 475-patient study published in the journal Diabetes Care, Vivus' Qsymia (phentermine and topiramate) reduced the annualized incidence rate of Type 2 diabetes by up to 78.7% in high-risk, overweight or obese patients with prediabetes or metabolic syndrome. Prediabetes is a condition in which a person has elevated blood sugar and a high risk of developing Type 2 diabetes.
-
CRN and NPA: Faulty vitamin D meta-analysis only looks at half of the supplement equation
WASHINGTON — Two associations representing the dietary supplement industry issued separate statements in response to what they characterized as a faulty meta-analysis, “Effects of Vitamin D Supplements on Bone Mineral Density: A Systematic Review and Meta-Analysis,” published last week in The Lancet.